Scarica l'app Stockscreener
135.79
0.16%
0.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine Biosciences director sells shares worth $269,167 - MSN
Reassessing Neurocrine Biosciences (NBIX) After Recent Share Price Weakness - Yahoo Finance
Neurocrine Biosciences (NBIX) Valuation Check After KINECT DCP Phase 3 Trial Failure - Sahm
How Neurocrine Biosciences Inc. stock benefits from tech adoption2025 Short Interest & Weekly Breakout Stock Alerts - ulpravda.ru
Is Neurocrine Biosciences (NBIX) Pricing Reflect Long Term Cash Flow Potential After Recent Weakness - simplywall.st
Why Neurocrine Biosciences Inc. stock could be next big winnerInsider Buying & Safe Swing Trade Setups - ulpravda.ru
Entry Recap: How Neurocrine Biosciences Inc stock benefits from tech adoptionMarket Growth Summary & Long-Term Capital Growth Strategies - moha.gov.vn
NBIX Analyst Downgrade by Morgan Stanley with Raised Price Targe - GuruFocus
Neurocrine Bio. stock rating downgraded by Morgan Stanley on competition - Investing.com Canada
How Neurocrine Biosciences Inc. stock performs in weak economyStock Liquidity Analysis & Affordable Growth Trading - ulpravda.ru
How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easingTechnical Analysis Insights & Crush the Market with Breakout Winners - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownHere's Why - MarketBeat
UBS lowers Neurocrine Bio. stock price target on competitive concerns By Investing.com - Investing.com Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 27.81% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
Allspring Global Investments Holdings LLC Has $52.39 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
(NBIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VIRGINIA RETIREMENT SYSTEMS ET Al Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
13,364 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Pacer Advisors Inc. - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by Zacks Research to "Hold" - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Stock Position Lessened by Simplify Asset Management Inc. - MarketBeat
Neurocrine Biosciences executive sells shares totaling $258,263 - MSN
Neurocrine Biosciences director Sherwin sells $1.6m in stock - MSN
Cwm LLC Has $11.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Burney Co. Has $4.05 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Neurocrine Biosciences Earnings Notes - Trefis
Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M - Eudaimonia and Co
Brighton Jones LLC Has $1.43 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero - Bloomberg Law News
Voya Investment Management LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What's Going On With Neurocrine Biosciences Stock Tuesday?Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga
Neurocrine’s valbenazine misses Phase III goals in DCP - The Pharma Letter
Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch - Sahm
Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq
Neurocrine's Ingrezza fails in phase 3 trial for dyskinetic cerebral palsy (NBIX:NASDAQ) - Seeking Alpha
Neurocrine's movement disorder treatment fails late-stage trial - marketscreener.com
Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints - marketscreener.com
Neurocrine’s phase 3 trial for cerebral palsy drug fails to meet endpoints - Investing.com
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PR Newswire
Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine’s Growth Story Runs Through INGREZZA And The Pipeline - Finimize
HC Wainwright & Co. maintains Neurocrine Biosciences (NBIX) buy recommendation - MSN
What hedge fund activity signals for Neurocrine Biosciences Inc. stock2025 Valuation Update & Weekly Sector Rotation Insights - Bölüm Sonu Canavarı
How Neurocrine Biosciences Inc. stock valuations compare to rivals2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Is Neurocrine Biosciences (NBIX) Quietly Recasting Its Long-Term Story Around Metabolic Disease Innovation? - simplywall.st
Merger Talk: Can Neurocrine Biosciences Inc. stock beat analyst upgrades2025 EndofYear Setup & Risk Managed Investment Entry Signals - moha.gov.vn
1.27%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):